ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2025-8-3-9-17ojrdrt-461Research ArticleЛУЧЕВАЯ ТЕРАПИЯRADIOTHERAPYЗначение лучевой терапии в комплексном лечении местно-распространенного рака поджелудочной железыValue of Radiotherapy in Complex Treatment of Locally Advanced Pancreatic Cancerhttps://orcid.org/0000-0002-0938-5213ВиноградоваЮ. Н.VinogradovaYu. N.

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, д. 70 

70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758

https://orcid.org/0000-0003-0182-4856КорытоваЛ. И.KorytovaL. I.

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, д. 70 

70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758

https://orcid.org/0009-0000-0717-7608БутримоваА. С.ButrimovaA. S.

Бутримова Анастасия Сергеевна 

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, д. 70 +79533244784 

Butrimova Anastasia Sergeevna 

70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758, +79533244784 

butrim2020@gmail.comhttps://orcid.org/0000-0002-7472-9676КорытовО. В.KorytovO. V.

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, д. 70 

70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758

https://orcid.org/0000-0002-7866-9607МешечкинА. В.MeshechkinA. V.

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, д. 70 

70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758

ИльинН. В.IlyinN. V.

197758, Санкт-Петербург, поселок Песочный, ул. Ленинградская, д. 70 

70, Leningradskaya str., Pesochny settlement, St. Petersburg, 197758

Российский научный центр радиологии и хирургических технологий им. академика А.М. Гранова Минздрава РоссииРоссияRussian Scientific Centre of Radiology and Surgical Technologies named after Academician A.M. Granov of the Ministry of Health of RussiaRussian Federation20252309202583917Copyright © Виноградова Ю.Н., Корытова Л.И., Бутримова А.С., Корытов О.В., Мешечкин А.В., Ильин Н.В., 20252025Виноградова Ю.Н., Корытова Л.И., Бутримова А.С., Корытов О.В., Мешечкин А.В., Ильин Н.В.Vinogradova Y.N., Korytova L.I., Butrimova A.S., Korytov O.V., Meshechkin A.V., Ilyin N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/461Цель

Цель: Ознакомить радиационных онкологов и специалистов смежных специальностей с различными аспектами перспективного комплексного подхода к пациентам с местно-распространенным раком поджелудочной железы.

Материалы и методы

Материалы и методы: В обзор включены данные отечественных и зарубежных статей, найденных в PubMed/MEDLINE, клинический случай.

Результаты

Результаты: В качестве клинического примера представлены пациенты с местно-распространенным раком поджелудочной железы, получившие химиотерапевтическое лечение с последующей лучевой терапией, продемонстрированы непосредственные результаты лечения.

Выводы

Выводы: Несмотря на преобладающую роль химиотерапии и хирургии в лечении рака поджелудочной железы (МРРПЖ), лучевая терапия, по-прежнему, занимает важное место в комплексном лечении этого заболевания как метод, способствующий улучшению местного контроля при резектабельном и погранично-резектабельном местно-распространенном РПЖ, а также при рецидивах заболевания. Однако данные о методиках, определении целевого объема и схемах фракционирования различаются в опубликованных российских и зарубежных исследованиях даже для пациентов со схожими исходными данными. Исходя из современных публикаций, возникла необходимость развития новых стратегий лечения РПЖ с обоснованным привлечением ЛТ.

Purpose: To familiarize radiation oncologists and specialists of related specialties with various aspects of a promising, comprehensive approach to patients with locally advanced pancreatic cancer.Materials and methods: The review includes data from domestic and foreign articles found in PubMed/MEDLINE, as well as a clinical case.Results: As a clinical example, patients with locally advanced pancreatic cancer who received chemotherapy followed by radiation therapy are presented, and the immediate results of treatment are demonstrated.Conclusions: Despite the predominant role of chemotherapy and surgery in the treatment of pancreatic cancer, radiation therapy still plays an important role in the comprehensive treatment of this disease as a method that improves local control in resectable, borderline resectable, locally advanced, and recurrent pancreatic cancer. However, there is a lack of data on the methods, target volume determination, and fractionation schemes.

злокачественные опухолиместно-распространенный рак поджелудочной железыхимиотерапиялучевая терапияmalignant tumourslocally advanced pancreatic cancerchemotherapyradiation therapyReferencesКаприн АД, Старинский ВВ, Шахзадова АО. Состояние онкологической помощи населению России в 2023 г. МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России. М., 2024.Kaprin AD, Starinsky VV, Shakhzadova AO. The State of Cancer Care in Russia in 2023. PA. Herzen Moscow Research Institute of Oncology – Branch of the National Medical Research Radiological Centre of the Russian Ministry of Health. – Moscow, 2024. (In Russ.).International Agency for Research on Cancer WHO Pancreas Source: Globocan 2020. 2020. Available from: http://gcoiarc-fr/today/data/factsheets/cancers/13-Pancreas-fact-sheetpdf.International Agency for Research on Cancer WHO Pancreas Source: Globocan 2020. 2020. Available from: http://gcoiarc-fr/today/data/factsheets/cancers/13-Pancreas-fact-sheetpdf.Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15(1):8-18. https://doi.org/10.1016/j.pan.2014.10.001 PMID: 25547205.Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15(1):8-18. https://doi.org/10.1016/j.pan.2014.10.001 PMID: 25547205.Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694-705. https://doi.org/10.3748/wjg.v22.i44.9694Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694-705. https://doi.org/10.3748/wjg.v22.i44.9694Franko J, Hsu HW, Thirunavukarasu P, et al. Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival. Eur J Surg Oncol. 2017;43(2):351-7. https://doi.org/10.1016/j.ejso.2016.10.021Franko J, Hsu HW, Thirunavukarasu P, et al. Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival. Eur J Surg Oncol. 2017;43(2):351-7. https://doi.org/10.1016/j.ejso.2016.10.021Шарабура ТМ, Бочкарева ТН. Роль лучевых методов лечения рака поджелудочной железы. Практическая онкология. 2025;26(1). https://doi.org/10.31917/2601058Sharabura TM, Bochkareva TN. The Role of Radiation Methods in the Treatment of Pancreatic Cancer. Practical Oncology. 2025;26(1). https://doi.org/10.31917/2601058 (In Russ.).Carrato A, Falcone A, Ducreux M, et al. Systematic review of the burden of pancreatic cancer in europe: Real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015; 46:201-11. https://doi.org/10.1007/s12029-015-9724-1.Carrato A, Falcone A, Ducreux M, et al. Systematic review of the burden of pancreatic cancer in europe: Real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015; 46:201-11. https://doi.org/10.1007/s12029-015-9724-1.Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled after 4 months of Gemcitabine with or without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844-53. https://doi.org/10.1001/jama.2016.4324Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled after 4 months of Gemcitabine with or without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844-53. https://doi.org/10.1001/jama.2016.4324Fietkau R, Grützmann R, Wittel UA, et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial. Strahlenther Onkol. 2021;197(1):8- 18. https://doi.org/10.1007/s00066-020-01680-2Fietkau R, Grützmann R, Wittel UA, et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial. Strahlenther Onkol. 2021;197(1):8- 18. https://doi.org/10.1007/s00066-020-01680-2Morganti AG, Valentini V, Macchia G, et al. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;59(5):1454-60. https://doi.org/10.1016/j.ijrobp.2004.01.035Morganti AG, Valentini V, Macchia G, et al. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;59(5):1454-60. https://doi.org/10.1016/j.ijrobp.2004.01.035Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94:755-65. https://doi.org/10.1016/j.ijrobp.2015.12.003Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94:755-65. https://doi.org/10.1016/j.ijrobp.2015.12.003Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128-37. https://doi.org/10.1002/cncr.29161Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128-37. https://doi.org/10.1002/cncr.29161Park JJ, Hajj C, Reyngold M, et al. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncol. 2017;56(12):1746-53. https://doi.org/10.1080/0284186X.2017.1342863Park JJ, Hajj C, Reyngold M, et al. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncol. 2017;56(12):1746-53. https://doi.org/10.1080/0284186X.2017.1342863Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654-68. https://doi.org/10.1200/JCO.2016.67.5561Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654-68. https://doi.org/10.1200/JCO.2016.67.5561Назаренко АВ, Знаткова ЯР, Сагайдак ИВ и др. Применение стереотаксической лучевой терапии для снятия болевого синдрома у пациентов с нерезектабельным раком поджелудочной железы. Вестник экспериментальной и клинической хирургии. 2018;11(3):208-12.Nazarenko AV, Znatkova YaR, Sagaidak IV, et al. Application of stereotactic radiation therapy for pain relief in patients with unresectable pancreatic cancer. Bulletin of Experimental and Clinical Surgery. 2018;11(3):208-12(In Russ.).Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94-S100. https://doi.org/10.1097/JTO.0b013e318074de34Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94-S100. https://doi.org/10.1097/JTO.0b013e318074de34Pontoriero A, Iatì G, Cacciola A, et al. Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost in Patients with Spinal Metastases. Technol Cancer Res Treat. 2020;19:1533033820904447. https://doi.org/10.1177/1533033820904447Pontoriero A, Iatì G, Cacciola A, et al. Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost in Patients with Spinal Metastases. Technol Cancer Res Treat. 2020;19:1533033820904447. https://doi.org/10.1177/1533033820904447Ferini G, Molino L, Bottalico L, et al. A small case series about safety and effectiveness of a hypofractionated electron beam radiotherapy schedule in five fractions for facial non melanoma skin cancer among frail and elderly patients. Rep Pract Oncol Radiother. 2021;26(1):66-72. https://doi.org/10.5603/RPOR.a2021.0013Ferini G, Molino L, Bottalico L, et al. A small case series about safety and effectiveness of a hypofractionated electron beam radiotherapy schedule in five fractions for facial non melanoma skin cancer among frail and elderly patients. Rep Pract Oncol Radiother. 2021;26(1):66-72. https://doi.org/10.5603/RPOR.a2021.0013Reyngold M, O’Reilly EM, Varghese AM, et al. Association of Ablative Radiation Therapy with Survival Among Patients with Inoperable Pancreatic Cancer. JAMA Oncol. 2021;7(5):735-8. https://doi.org/10.1001/jamaoncol.2021.0057Reyngold M, O’Reilly EM, Varghese AM, et al. Association of Ablative Radiation Therapy with Survival Among Patients with Inoperable Pancreatic Cancer. JAMA Oncol. 2021;7(5):735-8. https://doi.org/10.1001/jamaoncol.2021.0057Colbert LE, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017;2(3):403-15. https://doi.org/10.1016/j.adro.2017.02.004Colbert LE, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017;2(3):403-15. https://doi.org/10.1016/j.adro.2017.02.004Zhu X, Ju X, Cao Y, et al. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design. Int J Radiat Oncol Biol Phys. 2019;104(1):101-10. https://doi.org/10.1016/j.ijrobp.2019.01.075Zhu X, Ju X, Cao Y, et al. Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design. Int J Radiat Oncol Biol Phys. 2019;104(1):101-10. https://doi.org/10.1016/j.ijrobp.2019.01.075Koay EJ, Hanania AN, Hall WA, et al. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract Radiat Oncol. 2020;10(6):e495-e507. https://doi.org/10.1016/j.prro.2020.01.012Koay EJ, Hanania AN, Hall WA, et al. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract Radiat Oncol. 2020;10(6):e495-e507. https://doi.org/10.1016/j.prro.2020.01.012Parisi S, Ferini G, Cacciola A, et al. A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study. Radiol Med. 2022;127(2):214-9. https://doi.org/10.1007/s11547-021-01441-wParisi S, Ferini G, Cacciola A, et al. A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study. Radiol Med. 2022;127(2):214-9. https://doi.org/10.1007/s11547-021-01441-wComito T, Massaro M, Teriaca MA, et al. Can Stereotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer. Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study). Curr Oncol. 2023;30(7):7073-88. https://doi.org/10.3390/curroncol30070513Comito T, Massaro M, Teriaca MA, et al. Can Stereotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer. Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study). Curr Oncol. 2023;30(7):7073-88. https://doi.org/10.3390/curroncol30070513Zhu X, Liu W, Cao Y, et al. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial. E Clinical Medicine. 2022;55:101764. https://doi.org/10.1016/j.eclinm.2022.101764Zhu X, Liu W, Cao Y, et al. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial. E Clinical Medicine. 2022;55:101764. https://doi.org/10.1016/j.eclinm.2022.101764Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol. 2022;40:4008. https://doi.org/10.1200/JCO.2022.40.16Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol. 2022;40:4008. https://doi.org/10.1200/JCO.2022.40.16Strauss VY, Shaw R, Virdee PS, et al. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer. 2019;19:121. https://doi.org/10.1186/s12885-019-5307-zStrauss VY, Shaw R, Virdee PS, et al. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer. 2019;19:121. https://doi.org/10.1186/s12885-019-5307-zOar A, Lee M, Le H, et al. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer. 2021;21:936. https://doi.org/10.1186/s12885-021-08666-y.Oar A, Lee M, Le H, et al. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer. 2021;21:936. https://doi.org/10.1186/s12885-021-08666-y.Portales F, Ychou M, Samalin E, et al. Sequential treatment with gemcitabine/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial. J Clin Oncol. 2022;40:TPS4191. https://doi.org/10.1200/JCO.2022.40.16Portales F, Ychou M, Samalin E, et al. Sequential treatment with gemcitabine/nab-paclitaxel (GA) and FOLFIRINOX (FFX) followed by stereotactic MRI-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC): GABRINOX-ART phase 2, multicenter trial. J Clin Oncol. 2022;40:TPS4191. https://doi.org/10.1200/JCO.2022.40.16Zhang C, Yang H, Chang C, et al. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. BMJ Open. 2024;14(7):e084274. https://doi.org/10.1136/bmjopen-2024-084274 PMID: 39013651Zhang C, Yang H, Chang C, et al. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol. BMJ Open. 2024;14(7):e084274. https://doi.org/10.1136/bmjopen-2024-084274 PMID: 39013651

The authors declare that there are no conflicts of interest present.